Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WXD171-HlaH35L
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
WXD171-HlaH35L is an experimental recombinant probiotic vaccine candidate designed for the prevention of Staphylococcus aureus infections. It utilizes the probiotic bacterium Limosilactobacillus reuteri (strain WXD171) as a live delivery vehicle, genetically engineered to express HlaH35L on its surface. HlaH35L is a detoxified mutant form of the S. aureus alpha-hemolysin (Hla) toxin, where a single amino acid substitution (histidine 35 replaced with leucine) abolishes its hemolytic activity while retaining its immunogenic properties. Administered orally, the vaccine is intended to stimulate mucosal and systemic immune responses, including the production of secretory IgA and IL-17A, to protect against localized infections such as pneumonia and skin infections, as well as systemic infections like sepsis, including those caused by methicillin-resistant S. aureus (MRSA).
- Other names
- Limosilactobacillus reuteri WXD171-HlaH35LL. reuteri WXD171-HlaH35L
02
Targets
ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)Hla (Staphylococcus aureus alpha toxin)
Beyond the preview
Go deeper on WXD171-HlaH35L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WXD171-HlaH35L.